Medicis to license Abbott's Omnicef in USA
Abbott Laboratories and Medicis Pharmaceutical have reached an agreementin which the latter will promote Omnicef (cefdinir) capsules, Abbot's antibiotic for uncomplicated skin and skin structure infections, in the USA. The drug, which was launched three years ago on the US market (Marketletter October 12, 1998), is a semisynthetic cephalosporin which has good efficacy against Staphylococcus aureus and Streptococcus pyogenes. Jerry Wenker, vice president of Abbott, said that the new partnership "will expand the use of Omnicef into dermatology and beyond its strength in respiratory infections."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze